BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 14628994)

  • 1. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
    Kelly DL; Kreyenbuhl J; Love RC; Van-Duong Q; Conley RR
    J Clin Psychiatry; 2003 Sep; 64(9):1133-4. PubMed ID: 14628994
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two new atypical antipsychotics: advantages and disadvantages.
    Lemon MD
    S D J Med; 1998 Aug; 51(8):285-6. PubMed ID: 9724957
    [No Abstract]   [Full Text] [Related]  

  • 4. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
    Bobes J; Rejas J; Garcia-Garcia M; Rico-Villademoros F; García-Portilla MP; Fernández I; Hernández G;
    Schizophr Res; 2003 Jul; 62(1-2):77-88. PubMed ID: 12765747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new antipsychotic compounds: is a clinical choice algorithm possible?
    Wirshing WC
    West J Med; 1998 Jul; 169(1):43-4. PubMed ID: 9682633
    [No Abstract]   [Full Text] [Related]  

  • 6. Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine.
    Boot E; de Haan L
    Psychopharmacology (Berl); 2000 Jun; 150(3):347-8. PubMed ID: 10923763
    [No Abstract]   [Full Text] [Related]  

  • 7. The effects of novel antipsychotics on glucose and lipid levels.
    Wirshing DA; Boyd JA; Meng LR; Ballon JS; Marder SR; Wirshing WC
    J Clin Psychiatry; 2002 Oct; 63(10):856-65. PubMed ID: 12416594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of atypical antipsychotics in the treatment of schizophrenia.
    Jessen LM
    Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
    [No Abstract]   [Full Text] [Related]  

  • 9. Weight gain and antipsychotic medications.
    Aquila R; Emanuel M
    J Clin Psychiatry; 1999 May; 60(5):336-7. PubMed ID: 10362443
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.
    Bobes J; Garc A-Portilla MP; Rejas J; Hern Ndez G; Garcia-Garcia M; Rico-Villademoros F; Porras A
    J Sex Marital Ther; 2003; 29(2):125-47. PubMed ID: 12623765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
    Sernyak MJ; Leslie DL; Alarcon RD; Losonczy MF; Rosenheck R
    Am J Psychiatry; 2002 Apr; 159(4):561-6. PubMed ID: 11925293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
    Webster D; Devarajan S; Gallant J; Harris A; Kopala LC
    Schizophr Res; 2002 Jul; 56(1-2):187-9. PubMed ID: 12084432
    [No Abstract]   [Full Text] [Related]  

  • 13. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
    Rummel-Kluge C; Komossa K; Schwarz S; Hunger H; Schmid F; Lobos CA; Kissling W; Davis JM; Leucht S
    Schizophr Res; 2010 Nov; 123(2-3):225-33. PubMed ID: 20692814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.
    Atmaca M; Kuloglu M; Tezcan E; Gecici O; Ustundag B
    Schizophr Res; 2003 Mar; 60(1):99-100. PubMed ID: 12505146
    [No Abstract]   [Full Text] [Related]  

  • 19. Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.
    Weissman EM
    Schizophr Bull; 2002; 28(1):31-42. PubMed ID: 12047020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
    Meyer JM
    J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.